Company:  INSULET CORP (PODD)
Form Type:  10-Q
Filing Date:  8/7/2020 
CIK:  0001145197 
Address:  100 NAGOG PARK 
City, State, Zip:  ACTON, Massachusetts 01720 
Telephone:  978-600-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$248.52  
Change: 
0.19 (0.08%)  
Trade Time: 
Oct 19  
Market Cap: 
$16.32B
Trade PODD now with 

© 2020  
Description of Business
Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture and sale of its proprietary Omnipod® System, an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes, which we have been selling since 2005. The Omnipod System consists of the following: the Omnipod Insulin Management System ("Omnipod") and the Omnipod DASHTM Insulin Management System ("Omnipod DASH" or "DASH"), our next generation digital mobile Omnipod platform. There are two primary types of insulin therapy practiced today: multiple daily injection ("MDI") therapy using syringes or insulin pens; and pump therapy using insulin pumps. Insulin pumps are used to perform continuous subcutaneous insulin infusion and typically use a programmable device and an infusion set to administer insulin into the person's body.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Condensed Consolidated Financial Statements ...
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      FINANCIAL STATEMENTS
        CASH FLOW
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO